Overview

Imatinib in Adult Patients With Metastatic Ocular Melanoma

Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Oscar Lambret
Collaborators:
National Cancer Institute, France
Novartis
Treatments:
Imatinib Mesylate